Presidential Award- Oral
Yang Cheng (Singapore)
O-002 (41)
Inhibitory Receptor Co-expression Profiles Of T Cells Co-vary With Tissue Localization In HBV-associated Hepatocellular Carcinoma
Chien-Hao Huang (Taoyuan)
O-003 (164)
Systemic Administration of Toll-like receptor 9 Agonist Could Alter the Phenotype of Myeloid Derived Suppressor Cells with Subsequent Intrahepatic CD8+ T cell Expansion and Inhibits the Hepatoma Growth
Chau-Ting Yeh (Taoyuan)
O-006 (95)
Virological and host genetic biomarkers associated with time to clinical relapse following discontinuation of antiviral treatment in chronic hepatitis B patients.
Jia-Horng Kao (Taipei)
O-008 (141)
Improved Bone and Renal Safety at 1 Year after Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Results from 2 Phase 3 Studies in Chronic Hepatitis B (CHB) Patients from East Asia
Ming-lung Yu (Kaohsiung)
O-013 (33)
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for the treatment of HCV genotype 1b infection without baseline NS5A resistance-associated variants (DARING)-Final report